Incretin Therapies Significantly Lower Blood Pressure in Diabetes and Obesity

Incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, are well-established for managing type 2 diabetes and obesity due to their effects on glucose regulation and weight. However, hypertension (high blood pressure) is a common and dangerous comorbidity in these patient populations, significantly increasing cardiovascular risk. A comprehensive understanding of the precise and consistent impact of these diverse incretin therapies on blood pressure across various clinical settings and patient groups was needed to guide treatment strategies.

The meta-analysis revealed a consistent and statistically significant reduction in both systolic and diastolic blood pressure with incretin-based therapies across the board. These benefits were observed in patients both with and without pre-existing hypertension, suggesting a broad applicability. The most pronounced effects were generally seen with GLP-1 receptor agonists, which demonstrated superior reductions compared to DPP-4 inhibitors. The blood pressure improvements were found to be largely independent of weight loss, although weight reduction often contributed to additional benefits, indicating direct cardiovascular mechanisms. > The most impactful finding was a mean reduction in systolic blood pressure (SBP) of approximately -5.2 mmHg (95% CI: -5.8 to -4.6 mmHg, p<0.001) and diastolic blood pressure (DBP) of -2.6 mmHg (95% CI: -3.0 to -2.2 mmHg, p<001) across all incretin-based therapies compared to control groups, demonstrating a robust and clinically meaningful cardiovascular benefit. Specifically, GLP-1 receptor agonists achieved an average SBP reduction of -5.8 mmHg and DBP reduction of -2.9 mmHg, while DPP-4 inhibitors showed a more modest but still significant SBP reduction of -2.1 mmHg and DBP reduction of -1.0 mmHg.